Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines – A prospective multi-center study

Background: During the peak of Coronavirus disease (COVID-19) pandemic in Thailand when the emergence of delta variant reduced the efficacy of inactivated vaccine, Thailand had abundance of inactivated vaccine but mRNA vaccine was not available and the supply of adenoviral-vectored vaccine was limit...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Pawat Phuensan, Jarongkorn Sirimongkolkasem, Terapong Tantawichien, Jeerath Phannajit, Stephen J. Kerr, Pokrath Hansasuta, Prawat Chantharit, Adisorn Wongsa, Pusit Fuengfoo, Anutra Chittinandana, Kriengsak Vareesangthip, Methee Chayakulkeeree, Sureeporn Jangsirikul, Araya Schmidt, Kanyika Wanvimonsuk, Poramed Winichakoon, Rattagan Kajeekul, Wichai Prayoonwiwat, Rungsun Rerknimitr
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2024-01-01
סדרה:	Heliyon
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2405844023104543
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!